Efficacy and Safety of Continuous Every 2-Week Dosing of Ixekizumab Over 52 Weeks in Patients With Moderate-To-Severe Plaque Psoriasis in a Randomized Phase 3 Trial (IXORA-P)

British Journal of Dermatology - United Kingdom

doi 10.1111/bjd.16426